KPDS, “Conditionally-approved Tasigna’s clinical trial result must be disclosed”

Korean Pharmacists for Democratic Society(KPDS) announced to make a request for disclosure of the clinical trial result of Novartis’ ‘Tasigna.’

Novartis acquired conditional approval for the Phase 3 clinical trial of the myelogenous leukemia ‘Tasigna’ from the Ministry of Food and Drug Safety(MFDS) on December 2010.

Phase 3 conditional approval is a system to turn in the clinical trial result...